Notes to applicants for marketing authorizations on the production and quality control of monoclonal antibodies of murine origin intended for use in man. Committee for Proprietary Medicinal Products: Ad Hoc Working Party on Biotechnology/Pharmacy.
出版信息
J Biol Stand. 1989 Jul;17(3):213-22. doi: 10.1016/0092-1157(89)90013-9.
Abstract
摘要
相似文献
1
Notes to applicants for marketing authorizations on the production and quality control of monoclonal antibodies of murine origin intended for use in man. Committee for Proprietary Medicinal Products: Ad Hoc Working Party on Biotechnology/Pharmacy.人用鼠源单克隆抗体生产及质量控制的上市许可申请指南。专利药品委员会：生物技术/药学特设工作组。
J Biol Stand. 1989 Jul;17(3):213-22. doi: 10.1016/0092-1157(89)90013-9.
2
3
Notes to applicants for marketing authorizations on the production and quality control of medicinal products derived by recombinant DNA technology. Committee for Proprietary Medicinal Products: Ad Hoc Working Party on Biotechnology/Pharmacy.
J Biol Stand. 1989 Jul;17(3):223-31. doi: 10.1016/0092-1157(89)90014-0.
4
Notes to applicants for marketing authorizations on the pre-clinical biological safety testing of medicinal products derived from biotechnology (and comparable products derived from chemical synthesis). Committee for Proprietary Medicinal Products: Ad Hoc Working Party on Biotechnology/Pharmacy and Working Party on Safety of Medicines.
J Biol Stand. 1989 Jul;17(3):203-12. doi: 10.1016/0092-1157(89)90012-7.
5
Note for guidance. Production and quality control of cytokine products derived by biotechnological processes. Committee for Proprietary Medicinal Products: Ad hoc Working Party on Biotechnology/Pharmacy and Working Party on Safety Medicines.指导说明。生物技术工艺生产的细胞因子产品的生产与质量控制。专利药品委员会：生物技术/药学特设工作组及药品安全工作组。
Biologicals. 1991 Apr;19(2):125-31.
6
Production and quality control of human monoclonal antibodies. CPMP Working Party on Biotechnology/Pharmacy.人源单克隆抗体的生产与质量控制。人用药品委员会生物技术/药学工作组。
Pharmacol Toxicol. 1991 Jan;68(1):70-4.
7
Murine monoclonal antibody development.小鼠单克隆抗体的研发
Methods Mol Biol. 1995;51:123-37. doi: 10.1385/0-89603-275-2:123.
8
Implementing quality by design for biotech products: Are regulators on track?为生物技术产品实施设计质量：监管机构是否步入正轨？
MAbs. 2015;7(3):451-5. doi: 10.1080/19420862.2015.1023058.
9
Note for guidance. Guidelines for medicinal products derived from human blood and plasma. Committee for Proprietary Medicinal Products: Ad Hoc Working Party on Biotechnology/Pharmacy and Working Party on Safety Medicines.指导说明。人血和血浆衍生药品指南。专利药品委员会：生物技术/药学特设工作组和药品安全工作组。
Biologicals. 1992 Jun;20(2):159-64.
10
引用本文的文献
1
Rituximab and biosimilars - equivalence and reciprocity.利妥昔单抗及其生物类似药——等效性与互换性
Biosimilars. 2013 Jun 14;2013(3):19-25. doi: 10.2147/BS.S20681.
2
Supplementation of elderly Japanese men and women with fucoidan from seaweed increases immune responses to seasonal influenza vaccination.给日本老年男女补充海藻来源的岩藻多糖可增强其对季节性流感疫苗的免疫应答。
J Nutr. 2013 Nov;143(11):1794-8. doi: 10.3945/jn.113.179036. Epub 2013 Sep 4.
3
Subcutaneous immunoglobulin (16 or 20%) therapy in obese patients with primary immunodeficiency: a retrospective analysis of administration by infusion pump or subcutaneous rapid push.肥胖原发性免疫缺陷患者皮下免疫球蛋白（16%或 20%）治疗：输注泵或皮下快速推注给药的回顾性分析。
Clin Exp Immunol. 2013 Aug;173(2):365-71. doi: 10.1111/cei.12099.
4
Combination of comfrey root extract plus methyl nicotinate in patients with conditions of acute upper or low back pain: a multicentre randomised controlled trial.含紫草根提取物和烟碱酸甲酯的复方制剂治疗急性上背痛或下背痛患者的多中心随机对照试验。
Phytother Res. 2013 Jun;27(6):811-7. doi: 10.1002/ptr.4790. Epub 2012 Aug 8.
5
Transmissible spongiform encephalopathies and tissue cell culture.传染性海绵状脑病和组织细胞培养。
Cytotechnology. 2002 Jul;39(2):117-24. doi: 10.1023/A:1022935117274.
6
Effect of single doses of maraviroc on the QT/QTc interval in healthy subjects.单剂量马拉韦罗对健康受试者QT/QTc间期的影响。
Br J Clin Pharmacol. 2008 Apr;65 Suppl 1(Suppl 1):68-75. doi: 10.1111/j.1365-2125.2008.03138.x.
7
Safety evaluation of fixed combination piperaquine plus dihydroartemisinin (Artekin) in Cambodian children and adults with malaria.双氢青蒿素哌喹片（科泰复）用于柬埔寨疟疾儿童及成人的安全性评估
Br J Clin Pharmacol. 2004 Jan;57(1):93-9. doi: 10.1046/j.1365-2125.2003.01962.x.
8
Can lung deposition data act as a surrogate for the clinical response to inhaled asthma drugs?肺部沉积数据能否作为吸入性哮喘药物临床反应的替代指标？
Br J Clin Pharmacol. 2000 Jun;49(6):529-37. doi: 10.1046/j.1365-2125.2000.00106.x.
9
Analytical control procedures of immunoreactivity for IgG and Fab fragments specific to haptens.
Pharm Res. 1992 May;9(5):643-7. doi: 10.1023/a:1015802110647.
Zotero 插件